ACM
VIGL

Altium Capital Management’s Vigil Neuroscience VIGL Stock Holding History

Altium Capital Management’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,788
Closed -$144K – 136
2022
Q3 		$144K Buy
+15,788
New +$116K 0.05% 103

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Altium Capital Management's VIGL Position: Q4 2022 in Review

Altium Capital Management sold out of Vigil Neuroscience (VIGL) in Q4 2022, closing a stake of 15,788 shares — an estimated $144K sold.

Altium Capital Management first reported a position in VIGL in Q3 2022 and held it in 1 quarter. The position peaked at $144K in Q3 2022. 37 funds tracked by Wall St. Rank hold VIGL as of Q4 2022.

  • Altium Capital Management reported no remaining Vigil Neuroscience position as of Q4 2022 after selling out during the quarter.
  • Altium Capital Management sold 15,788 Vigil Neuroscience shares in Q4 2022, an estimated $144K.
  • Altium Capital Management first reported a position in Vigil Neuroscience in Q3 2022 and held it in 1 quarter.
  • Altium Capital Management's Vigil Neuroscience position peaked at $144K in Q3 2022.
  • 37 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q4 2022.

Based on Altium Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.